| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53706 [P. A. N., A. T-D.]; Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 [P. A. N., B. E. S.]; Department of Community Medicine, Dartmouth Medical School, Hanover, New Hampshire 03756 [L. T-E., J. A. B.]; Departments of Epidemiology [K. M. E., W. C. W., M. J. S.] and Nutrition [W. C. W., M. J. S.], Harvard School of Public Health, Boston, Massachusetts 02115; and Channing Laboratory, Harvard Medical School and Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts 02115 [W. C. W., M. J. S.]
Epidemiological evidence now consistently supports a modestincrease in breast cancer risk among women using postmenopausal hormones, usually estrogens.Less is known regarding how the addition of progestin affects breast cancer risk. The objective of this study was to investigate the type and duration of postmenopausal therapy and breast cancer risk. We performed a multicenter population-based case-control study set in Massachusetts, New Hampshire, and Wisconsin. The subjects were 5298 postmenopausal women (age range, 50–79 years) with a new diagnosis of invasive breast cancer from statewide tumor registries. For comparison, 5571 controls were randomly selected from population lists. Participants completed a structured telephone interview covering hormone use and breast cancer risk factors. Multivariable regression models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs). The RR for breast cancer increased with longer durations of hormone use, about 2%/year for estrogen alone (RR, 1.02; 95% CI, 1.01–1.03) and 4%/year for estrogen-progestin use (RR, 1.04; 95% CI, 1.01–1.08). Estrogen-progestin use that was both recent and long term (>5 years in duration) was more strongly associated with breast cancer risk (RR, 1.57; 95% CI, 1.15–2.14) than similar use of estrogen alone (RR, 1.39; 95% CI, 1.17–1.65). In estrogen-progestin users, risks were similar for sequential and continuous use regimens but perhaps stronger for lobular than ductal breast cancer. Use of progestin alone was associated with a doubling of risk (RR, 2.09; 95% CI, 1.07–4.07 for ever use versus nonuse). Estrogen-progestin use, both sequential and continuous, appears to be more strongly associated with risk of breast cancer than use of estrogen alone.
This article has been cited by other articles:
|
|
 |
|
  P. A. Newcomb, K. M. Egan, A. Trentham-Dietz, L. Titus-Ernstoff, J. A. Baron, J. M. Hampton, M. J. Stampfer, and W. C. Willett Prediagnostic Use of Hormone Therapy and Mortality After Breast Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 864 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fournier, A. Fabre, S. Mesrine, M.-C. Boutron-Ruault, F. Berrino, and F. Clavel-Chapelon Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor-Defined Invasive Breast Cancer J. Clin. Oncol., March 10, 2008; 26(8): 1260 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Li, K. E. Malone, P. L. Porter, T. J. Lawton, L. F. Voigt, K. L. Cushing-Haugen, M. G. Lin, X. Yuan, and J. R. Daling Relationship between Menopausal Hormone Therapy and Risk of Ductal, Lobular, and Ductal-Lobular Breast Carcinomas Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 43 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Li and J. R. Daling Changes in Breast Cancer Incidence Rates in the United States by Histologic Subtype and Race/Ethnicity, 1995 to 2004 Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2773 - 2780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Biglia, L. Mariani, L. Sgro, P. Mininanni, G. Moggio, and P. Sismondi Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment Endocr. Relat. Cancer, September 1, 2007; 14(3): 549 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Brinton and J. V. Lacey Jr. Hormones and Breast Cancer: What's the Story? Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1697 - 1699. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shantakumar, M. B. Terry, A. Paykin, S. L. Teitelbaum, J. A. Britton, P. G. Moorman, S. B. Kritchevsky, A. I. Neugut, and M. D. Gammon Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk Am. J. Epidemiol., May 15, 2007; 165(10): 1187 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Zhang, J. E. Manson, K. M. Rexrode, N. R. Cook, J. E. Buring, and I-M. Lee Use of Oral Conjugated Estrogen Alone and Risk of Breast Cancer Am. J. Epidemiol., March 1, 2007; 165(5): 524 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lyytinen, E. Pukkala, and O. Ylikorkala Breast Cancer Risk in Postmenopausal Women Using Estrogen-Only Therapy Obstet. Gynecol., December 1, 2006; 108(6): 1354 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Barlow, E. White, R. Ballard-Barbash, P. M. Vacek, L. Titus-Ernstoff, P. A. Carney, J. A. Tice, D. S. M. Buist, B. M. Geller, R. Rosenberg, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst, September 6, 2006; 98(17): 1204 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Li, J. R. Daling, K. E. Malone, L. Bernstein, P. A. Marchbanks, J. M. Liff, B. L. Strom, M. S. Simon, M. F. Press, J. A. McDonald, et al. Relationship between Established Breast Cancer Risk Factors and Risk of Seven Different Histologic Types of Invasive Breast Cancer. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 946 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Greiser, E. M. Greiser, and M. Doren Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials Hum. Reprod. Update, November 1, 2005; 11(6): 561 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Collins, J. M. Blake, and P. G. Crosignani Breast cancer risk with postmenopausal hormonal treatment Hum. Reprod. Update, November 1, 2005; 11(6): 545 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Tworoger, S. A. Missmer, R. L. Barbieri, W. C. Willett, G. A. Colditz, and S. E. Hankinson Plasma Sex Hormone Concentrations and Subsequent Risk of Breast Cancer Among Women Using Postmenopausal Hormones J Natl Cancer Inst, April 20, 2005; 97(8): 595 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Li, J. R. Daling, and K. E. Malone Age-Specific Incidence Rates of In situ Breast Carcinomas by Histologic Type, 1980 to 2001 Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 1008 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Colditz Estrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer Clin. Cancer Res., January 15, 2005; 11(2): 909s - 917s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Egan, P. A. Newcomb, C. B. Ambrosone, A. Trentham-Dietz, L. Titus-Ernstoff, J. M. Hampton, M. T. Kimura, and H. Nagase STK15 polymorphism and breast cancer risk in a population-based study Carcinogenesis, November 1, 2004; 25(11): 2149 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Daling, K. E. Malone, D. R. Doody, L. F. Voigt, L. Bernstein, P. A. Marchbanks, R. J. Coates, S. A. Norman, L. K. Weiss, G. Ursin, et al. Association of Regimens of Hormone Replacement Therapy to Prognostic Factors among Women Diagnosed with Breast Cancer Aged 50-64 Years Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1175 - 1181. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. I. Li, R. E. Moe, and J. R. Daling Risk of Mortality by Histologic Type of Breast Cancer Among Women Aged 50 to 79 Years Arch Intern Med, October 13, 2003; 163(18): 2149 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Li, K. E. Malone, P. L. Porter, N. S. Weiss, M.-T. C. Tang, and J. R. Daling The Relationship between Alcohol Use and Risk of Breast Cancer by Histology and Hormone Receptor Status among Women 65-79 Years of Age Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1061 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Gapstur, P. Lopez, L. A. Colangelo, J. Wolfman, L. Van Horn, and R. E. Hendrick Associations of Breast Cancer Risk Factors with Breast Density in Hispanic Women Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1074 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Register, M. J. Jayo, and M. S. Anthony Soy Phytoestrogens Do Not Prevent Bone Loss in Postmenopausal Monkeys J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4362 - 4370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. I. Li, K. E. Malone, P. L. Porter, N. S. Weiss, M.-T. C. Tang, K. L. Cushing-Haugen, and J. R. Daling Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer JAMA, June 25, 2003; 289(24): 3254 - 3263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wedren, T. R. Rudqvist, F. Granath, E. Weiderpass, M. Ingelman-Sundberg, I. Persson, and C. Magnusson Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk Carcinogenesis, April 1, 2003; 24(4): 681 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Li, B. O. Anderson, J. R. Daling, and R. E. Moe Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma JAMA, March 19, 2003; 289(11): 1421 - 1424. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
